Target intelligence / Profile preview

Alpha-L-fucosidase 2 (FUCA2)

Target
FUCA2
Molecular classification
Enzyme, Glycosidase, Glycosyl hydrolase 29 family
01

Overview

Alpha-L-fucosidase 2 (FUCA2) is a secreted enzyme responsible for the removal of terminal fucose residues from glycoproteins and other glycoconjugates, playing a critical role in modulating extracellular glycan structures[1][3]. It is a member of the glycosyl hydrolase 29 family and catalyzes the hydrolysis of alpha-1,6-linked fucose joined to the reducing-end N-acetylglucosamine of carbohydrate moieties. The enzyme is essential for microbial adhesion, such as facilitating Helicobacter pylori binding in gastric tissues. FUCA2 is also upregulated in several cancers (correlating with poor prognosis and immunosuppression), linked to cardiovascular dysfunctions, and participates in immune cell signaling[1][3]. Its expression can be modulated by cytokines like interferon-gamma, suggesting a broader role in immune response and disease pathogenesis[1][3].

Other names
Plasma alpha-L-fucosidasePSEC0151UNQ227/PRO260Alpha-L-fucosidase 2MGC1314dJ20N2.5Alpha-L-fucoside fucohydrolase 2α-L-fucosidase 2plasma fucosidasea-L-fucosidase 2
02

Mechanism of action

Enzymatic hydrolysis of terminal alpha-1,6-linked fucose residues from glycoproteins and glycoconjugates[1][3]

03

Biological functions

Fucose metabolic processGlycoside catabolismModulation of extracellular glycan structuresCell adhesion (indirectly, via glycosylation)Immune regulation (modulating Th1/Th2 cytokine response)
04

Disease associations

Cancer (upregulated, correlates with poor prognosis and immunosuppressive tumor microenvironment)Cardiovascular disease (involved in sickle cell diastolic dysfunction)Infection (facilitates Helicobacter pylori adhesion in gastric cancer)Other (potential roles in inflammation and metabolic disease)
05

Safety considerations

Targeting may impact normal glycosylation patterns, potentially affecting immune surveillance and host–microbe interactions[1]
06

Biomarkers

Upregulation in tumors correlates with poor survival and immunosuppression[1]

Beyond the preview

Go deeper on Alpha-L-fucosidase 2 (FUCA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-L-fucosidase 2 (FUCA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call